Altavo, a Dresden-based medical technology startup specialising in AI-driven voice rehabilitation, has successfully raised €3 million in a Series A2 funding round, strengthening its position in the rapidly evolving assistive healthcare technology space.
The financing round, closed on January 12, 2026, was led by a European investor consortium including Novalis Biotech and Beteiligungsmanagement Thüringen. The fresh capital will be used to accelerate product development, clinical validation, and commercialisation of Altavo’s Artificial Voice technology.
Restoring Natural Speech Through AI and Radar Sensing
Altavo’s flagship innovation is an Artificial Voice system designed to help people who have lost their ability to speak—such as patients who have undergone a laryngectomy or individuals on mechanical ventilation—regain a natural-sounding version of their own voice.
At the core of the solution is a proprietary “silent speech” technology, developed in close collaboration with researchers from Dresden University of Technology. The system combines non-invasive radar sensing with advanced artificial intelligence algorithms to detect subtle muscle movements associated with speech, even when no sound is produced.
By translating these signals into audible speech, Altavo’s technology opens up entirely new possibilities for voice prosthetics and silent human–machine interaction, with significant implications for both healthcare and assistive communication.
Strong European Investor Backing
Alongside lead investors Novalis Biotech and Beteiligungsmanagement Thüringen, the Series A2 round also saw participation from TGFS Technologiegründerfonds Sachsen, High-Tech Gründerfonds, TUDAG TU Dresden AG, Ostwerk GmbH, and several private investors.
Altavo said the continued support from existing investors, combined with new strategic backers, reflects strong confidence in both its clinical progress and commercial potential.
“We are grateful for the strong backing of our European investor group and are pleased to welcome new partners in this round,” said Rudolf von Bünau, CEO and co-founder of Altavo. “This Series A2 round positions us extremely well for the next phase on our path toward delivering an Artificial Voice for voiceless people.”
Funding to Drive Clinical and Product Development
The newly raised capital will primarily be used to support clinical studies, further technology refinement, and the development of a market-ready medical device. Altavo’s team is focused on ensuring regulatory readiness while maintaining high standards of safety, accuracy, and usability.
Investors highlighted the startup’s ability to translate academic research into a scalable commercial product as a key reason for backing the round.
“Altavo’s development progress, clinical achievements, and experienced leadership team convinced us to co-lead this financing round,” said Jaroslav Belotserkovsky, Investment Manager at Novalis Biotech.
A Model for Research-to-Startup Translation
Altavo is increasingly being viewed as a benchmark for successful research commercialisation in central Germany. Its collaboration with academic institutions is supported by public funding from the State of Saxony, co-financed by the European Union under the “B3 / MUSIK” project within the SEMECO Cluster for Future.
“Altavo remains a prime example of how academic excellence can be translated into a successful startup across state boundaries,” said Michael Thiele, Investment Manager at Beteiligungsmanagement Thüringen, along with Sören Schuster, CEO of TGFS Technologiegründerfonds Sachsen.
About Altavo
Founded in February 2021, Altavo GmbH is headquartered in Dresden, with additional operations in Jena. The company employs a team of 16 professionals with expertise spanning AI and data science, speech technology, radio frequency engineering, medical devices, and speech therapy.
With its latest funding round, Altavo aims to significantly improve the quality of life for aphonic and severely voice-impaired patients, while laying the groundwork for future applications in silent communication and human–machine interfaces.
Ruchi Kumar is the associate editor at Entrepreneur News Network and TVW News India, where she leads editorial strategy, brand storytelling, and startup ecosystem coverage. With a strong focus on innovation, business, and marketing insights, he curates impactful narratives that spotlight India’s evolving entrepreneurial landscape.